ECM
ANIK icon

Element Capital Management’s Anika Therapeutics ANIK Stock Holding History

Element Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,495
Closed -$408K – 272
2019
Q1 		$408K Buy
+13,495
New +$462K 0.01% 500

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Element Capital Management's ANIK Position: Q2 2019 in Review

Element Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2019, closing a stake of 13,495 shares — an estimated $408K sold.

Element Capital Management first reported a position in ANIK in Q1 2019 and held it in 1 quarter. The position peaked at $408K in Q1 2019. 165 funds tracked by Wall St. Rank hold ANIK as of Q2 2019.

  • Element Capital Management reported no remaining Anika Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 13,495 Anika Therapeutics shares in Q2 2019, an estimated $408K.
  • Element Capital Management first reported a position in Anika Therapeutics in Q1 2019 and held it in 1 quarter.
  • Element Capital Management's Anika Therapeutics position peaked at $408K in Q1 2019.
  • 165 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.